Lactobacillus fermentum V3 ameliorates colitis-associated tumorigenesis by modulating the gut microbiome.

ABSTRACT: Lactobacillus spp., a common probiotic used as a dietary supplement, is good for the digestive system. However, its anti-cancer activity still remains unclear. In this study, we aim to examine the effect of Lactobacillus fermentum, Lactobacillus acidophilus and Lactobacillus rhamnosus on azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colitis-associated cancer. Male ICR mice were injected with 10 mg/kg AOM and 2.5% DSS via drinking water, and then fed with different Lactobacillus (1 × 108 CFU/day) for 14 weeks. The colonic tissues were collected for biomedical analysis, and gut microbiota profiling was detected by next generation high-throughput sequencing comparing to the 16S rRNA gene. We found that pretreatment with Lactobacillus fermentum (Lac.ferm) significantly inhibits colonic

SUBMITTER: Chou YC 

PROVIDER: S-EPMC7191089 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature